Skip to main content
. 2016 Jul 6;5(9):2657–2665. doi: 10.1002/cam4.810

Table 1.

Study characteristics among populations‐based controls by study population and DNA extraction method

N Gender Age BMI Smoking ever (%) LTL median (IQR)
Male (%) Mean years (SD) Mean kg/m2 (SD)
Study [reference number]
The Study of Reflux Disease (SRD) 12 100 60 (60.0) 51.7 (12.5) 27.7 (4.7) 48 (48.0) 1.03 (0.92–1.21)
The Factors Influencing the Barrett's/Adenocarcinoma Relationship (FINBAR) Study 13 91 82 (90.1) 61.7 (13.8) 27.1 (4.0) 55 (60.8) 0.80 (0.70–0.96)
The Study of Digestive Health (SDH) 14 104 75 (72.1) 61.3 (11.0) 27.4 (5.1) 56 (53.9) 0.87 (0.77–0.97)
The Epidemiology and Incidence of Barrett's Oesophagus (EIBO) Study 15 100 71 (71.0) 64.0 (10.1) 28.7 (4.6) 59 (59.0) 0.98 (0.89–1.11)
The Los Angeles Multi‐ethnic (LAM) Study 16 53 47 (88.7) 61.0 (9.8) 25.9 (5.2) 33 (62.3) 0.71 (0.67–0.84)
The Australian Cancer Study (ACS) 17 242 225 (92.9) 63.3 (9.5) 27.7 (4.7) 148 (61.2) 0.94 (0.84–1.06)
The Swedish Esophageal and Cardia Cancer (SECC) Study 18 46 40 (87.0) 66.6 (8.2) 23.5 (1.9) 25 (54.4) 0.87 (0.76–0.99)
DNA extraction method (company/reference)
Gentra Puregene DNA purification kit (Qiagen, Hilden, Germany)a 237 193 (81.4) 63.6 (11.5) 27.1 (4.4) 139 (59.1) 0.91 (0.77–1.03)
Protein Salting Out 19, b 346 300 (86.7) 62.7 (10.0) 27.6 (4.8) 204 (59.0) 0.92 (0.80–1.03)
Qiagen QIAamp DNA Blood kit (Qiagen)c 53 47 (88.7) 61.0 (9.8) 25.6 (5.2) 33 (62.3) 0.71 (0.67–0.84)
5‐Prime (5‐Prime, Hilden, Germany)d 100 60 (60.0) 51.7 (12.5) 27.5 (4.7) 48 (48.0) 1.03 (0.92–1.21)
Total 736 604 (82.1) 61.4 (11.5) 27.3 (4.7) 425 (57.8) 0.92 (0.79–1.04)

Extraction method used in aFINBAR, EIBO, and SECC study; bSDH and ASC study; cLAM study; dSRD study. LTL, leukocyte telomere length; IQR, interquartile range; SD, standard deviation; BMI, body mass index.